IMMUNOPHARMACOLOGY STUDIES RELATED TO IN VITRO INFECTION WITH HTLV-I NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IMMUNOPHARMACOLOGY STUDIES RELATED TO IN VITRO INFECTION WITH HTLV-I

Dev Oncol; 44:309-19 1987. Unique Identifier : AIDSLINE ICDB/88639589
Grandori C; Graziani G; Perno CF; D'Onofrio C; Bonmassar E; Dept. of Experimental Medicine and Biochemical Science, Second; Univ. of Rome, Via Orazio Raimondo, I-00173 Rome, Italy

Abstract: Ficoll-separated mononuclear cells from human umbilical cord blood (cord blood lymphocytes, CBL) or adult peripheral blood were treated with human beta interferon (IFN: 1,000 U/ml) or PCF-39 (N-9 arginil hypoxanthine derivative, 1 or 100 ug/ml) for 16 hr at 37 C. Cells were then tested for cell mediated-natural cytotoxicity against natural killer-susceptible K562 targets or a variety of human T-cell leukemia/lymphoma virus type I (HTLV-I)-positive lymphoblasts using a 4-hr 52Cr-release assay. Some pretreated lymphocytes also were cocultivated with irradiated virus-donor MT-2 cells (CBL cell line infected in vitro with HTLV-I), and later tested for nonspecific or MT-2-specific cytotoxicity and for virus infections monitored by cellular expression of HTLV-I P19 protein. The agents increased immune functions in selected experimental conditions and reduced virus infection by increasing target cell resistance and by decreasing MT-2 infectivity. Limited or no influence of the agents on virus transmission was found when target leukemic rather than immunocompetent cells were used in the donor-recipient cocultures. These preliminary results suggest a possible role of immunologic functions and immunomodulating agents on in vitro HTLV-I infection. (21 Refs)
Keywords: Adjuvants, Immunologic/*PHARMACOLOGY Cell Line Cytotoxicity, Immunologic/*DRUG EFFECTS Human Hypoxanthines/*PHARMACOLOGY HTLV-BLV Infections/*IMMUNOLOGY Interferon Type I/*PHARMACOLOGY T-Lymphocytes/DRUG EFFECTS JOURNAL ARTICLE

KWDadjuvants,immunologic/KWDpharmacologycelllinecytotoxicity,immunologic/KWDdrugeffectshumanhypoxanthines/KWDpharmacologyhtlv-blvinfections/KWDimmunologyinterferontypei/KWDpharmacologyt-lymphocytes/drugeffectsjournalarticle
880330
M8830436

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .